Me. Stockton et K. Rasmussen, OLANZAPINE, A NOVEL ATYPICAL ANTIPSYCHOTIC, REVERSES D-AMPHETAMINE-INDUCED INHIBITION OF MIDBRAIN DOPAMINE CELLS, Psychopharmacology, 124(1-2), 1996, pp. 50-56
This study compared the ability of the novel atypical antipsychotic ol
anzapine with that of clozapine to reverse the d-amphetamine-induced i
nhibition of substantia nigra (A9) and ventral tegmental area (A10) do
pamine (DA) cells. Extracellular single-unit recordings were made from
A9 and A10 DA cells in anesthetized rats. When administered alone, ne
ither olanzapine nor clozapine altered the firing rate of A9 or A10 DA
cells. Administration of d-amphetamine (0.5, 1.0, and 2.0 mg/kg, IV,
decreased the firing rate of A9 and A10 DA cells. Olanzapine completel
y reversed the inhibitory effects of d-amphetamine on A10 DA cells (ED
(100)=0.18 mg/kg, IV) and on A9 DA cells (ED(100)=1.0 mg/kg, IV). Cloz
apine completely reversed the inhibitory effects of d-amphetamine on A
10 DA cells (ED(100)=3.8 mg/kg, IV), but only partially reversed the e
ffects of d-amphetamine on A9 DA cells at the highest dose tested (8.0
mg/kg, IV). Thus, olanzapine, like clozapine, was more potent in reve
rsing the effects of d-amphetamine on A10 than A9 DA cells. In additio
n, olanzapine was more potent than clozapine in the reversal of d-amph
etamine effects on A9 and A10 DA cells. These results indicate that ol
anzapine and clozapine have similar effects on DA unit activity and pr
edict that olanzapine should have an atypical antipsychotic profile in
man.